Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue
Contract development and manufacturing organisation (CDMO) Cohance Lifesciences (formerly Suven Pharmaceuticals) reported ₹45.19 crore loss on a consolidated basis for the quarter ended June compared to the ₹46.40 crore net profit in the year earlier period. Total income declined to ₹434.51 crore (₹563.48 crore), which the company attributed to shipment phasing in pharma CDMO, a…
Read More “Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue” »